{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:49:03Z","timestamp":1789343343157,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105059","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:43:01Z","timestamp":1764348181000},"page":"105059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Prognostic value, clinical relevance, and methodological gaps of tumor burden in neuroendocrine tumors (NETs): A systematic review of phase III randomized trials of medical therapies"],"prefix":"10.1016","volume":"217","author":[{"given":"Giulia","family":"Arrivi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rinzivillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Filice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Modica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Partelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Elisa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-4289","authenticated-orcid":false,"given":"Francesco","family":"Panzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2025.105059_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamaoncol.2024.5937","article-title":"Gastroenteropancreatic neuroendocrine tumor incidence by sex and age in the US","volume":"11","author":"Abboud","year":"2025","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105059_bib2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1677\/ERC-09-0042","article-title":"Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study","volume":"16","author":"Ahmed","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105059_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11154-020-09581-6","article-title":"PRRT: Identikit of the perfect patient","volume":"22","author":"Albertelli","year":"2021","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105059_bib4","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.3390\/cancers15082249","article-title":"Neuroendocrine tumors: Genomics and molecular biomarkers with a focus on metastatic disease","volume":"15","author":"Alexander","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105059_bib5","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.22272","article-title":"Lanreotide autogel every 6 weeks vs lanreotide microparticles every 3 weeks in well-differentiated NETs: A phase III study","volume":"107","author":"Bajetta","year":"2006","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105059_bib6","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0337","article-title":"Treatment of advanced BP-NETs with lanreotide autogel\/depot vs placebo: the SPINET Phase III study","volume":"31","author":"Baudin","year":"2024","journal-title":"Endocr. Relat. Cancer"},{"issue":". 5","key":"10.1016\/j.critrevonc.2025.105059_bib7","doi-asserted-by":"crossref","first-page":"S750","DOI":"10.1016\/j.annonc.2024.08.1201","article-title":"Multivariable analysis of streptozotocin + 5-FU and everolimus sequences in advanced pancreatic NETs (SEQTOR trial)","volume":"35","author":"Capdevila Castillon","year":"2024","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105059_bib8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumours","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105059_bib9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12020-020-02475-2","article-title":"Lanreotide autogel\/depot in advanced enteropancreatic NETs: Final OLE results","volume":"71","author":"Caplin","year":"2021","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105059_bib10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase III trial of cabozantinib in advanced NETs","volume":"392","author":"Chan","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105059_bib11","first-page":"359","article-title":"Critical updates to the AJCC v9 staging for GEP-NETs","volume":"74","author":"Chauhan","year":"2024","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105059_bib12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00259-022-05971-x","article-title":"Tumor burden quantification using DOTA-NOC PET\/CT in NETs","volume":"50","author":"Chen","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105059_bib13","doi-asserted-by":"crossref","first-page":"18614","DOI":"10.1038\/s41598-019-55156-0","article-title":"DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors","volume":"9","author":"Cives","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.105059_bib14","unstructured":"ClinicalTrials.gov (accessed June 30, 2025). \u3008https:\/\/clinicaltrials.gov\/search?cond=Neuroendocrine%20Tumors\u3009."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105059_bib15","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1677\/ERC-09-0104","article-title":"Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710","volume":"16","author":"Dahan","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105059_bib16","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105059_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12885-018-5257-x","article-title":"Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors","volume":"19","author":"Dromain","year":"2019","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105059_bib18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1159\/000510445","article-title":"Tumor growth rate to predict the outcome of patients with neuroendocrine tumors: Performance and sources of variability","volume":"111","author":"Dromain","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105059_bib19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1677\/ERC-08-0301","article-title":"Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma","volume":"16","author":"Durante","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105059_bib20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","article-title":"Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor","volume":"2","author":"Engstrom","year":"1984","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105059_bib21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.12-1108","article-title":"Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the randomized, placebo-controlled RADIANT-2 study","volume":"143","author":"Fazio","year":"2013","journal-title":"Chest"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105059_bib22","doi-asserted-by":"crossref","first-page":"8432","DOI":"10.3390\/ijms26167814","article-title":"Decoding pancreatic neuroendocrine tumors: Molecular profiles, biomarkers, and pathways to personalized therapy","volume":"26","author":"Galasso","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3.","key":"10.1016\/j.critrevonc.2025.105059_bib23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JCO.2021.39.3_suppl.360","article-title":"A phase II\/III randomized double-blind study of octreotide LAR with axitinib versus octreotide LAR with placebo in advanced G1\u2013G2 non-pancreatic NETs (AXINET trial-GETNE-1107)","volume":"39","author":"Garcia-Carbonero","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105059_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg","year":"2022","journal-title":"J. Neuroendocrinol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105059_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13332","article-title":"ENETS 2023 guidance paper for appendiceal neuroendocrine tumours (aNET)","volume":"35","author":"Kaltsas","year":"2023","journal-title":"J. Neuroendocrinol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105059_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13343","article-title":"ENETS 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J. Neuroendocrinol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105059_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13423","article-title":"ENETS 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J. Neuroendocrinol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105059_bib28","doi-asserted-by":"crossref","first-page":"e1082","DOI":"10.1634\/theoncologist.2018-0672","article-title":"Value of tumour growth rate as an early biomarker of outcome in neuroendocrine tumours: The GREPONET study","volume":"24","author":"Lamarca","year":"2019","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105059_bib29","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1210\/jc.2016-3732","article-title":"Functional imaging in the follow-up of enteropancreatic neuroendocrine tumours: Clinical usefulness and indications","volume":"102","author":"Merola","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2025.105059_bib30","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.105059_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102998","article-title":"The importance of education and training in neuroendocrine neoplasms: Challenges and opportunities for multidisciplinary management","volume":"139","author":"Panzuto","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.105059_bib32","article-title":"Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: A missed opportunity for European patients?","volume":"55","author":"Panzuto","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105059_bib33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1634\/theoncologist.2016-0351","article-title":"Stage IV gastro-entero-pancreatic neuroendocrine neoplasms: A risk score to predict clinical outcome","volume":"22","author":"Panzuto","year":"2017","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105059_bib34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MPA.0000000000000032","article-title":"Advanced digestive neuroendocrine tumours: Metastatic pattern as an independent prognostic factor","volume":"43","author":"Panzuto","year":"2014","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105059_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12020-023-03649-4","article-title":"Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: Bridging tumour registry data with the ITANET national database","volume":"84","author":"Panzuto","year":"2024","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105059_bib36","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.pan.2019.09.015","article-title":"Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: Comparison between pancreatic and gastrointestinal sites","volume":"19","author":"Panzuto","year":"2019","journal-title":"Pancreatology"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105059_bib37","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/ERC-08-0017","article-title":"Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours","volume":"15","author":"Pape","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"issue":"9808","key":"10.1016\/j.critrevonc.2025.105059_bib38","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide LAR for advanced NETs with carcinoid syndrome (RADIANT-2)","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105059_bib39","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1159\/000518873","article-title":"NETest: A systematic review focusing on its prognostic and predictive role","volume":"112","author":"Puliani","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105059_bib40","first-page":"607","article-title":"A classification prognostic score to predict overall survival in stage IV well-differentiated NETs. Endocrine-Related Cancer","volume":"25","author":"Pusceddu","year":"2018"},{"issue":"28","key":"10.1016\/j.critrevonc.2025.105059_bib41","doi-asserted-by":"crossref","first-page":"44841","DOI":"10.18632\/oncotarget.8601","article-title":"How do RADIANT trial results impact the management of NET patients? A systematic review","volume":"7","author":"Pusceddu","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105059_bib42","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/s11864-023-01152-6","article-title":"Liver-directed therapy for neuroendocrine tumour metastases in the era of PRRT","volume":"24","author":"Rabei","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105059_bib43","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105059_bib44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: Consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","journal-title":"Virchows Arch."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105059_bib45","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro)endocrine tumors: Consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch."},{"issue":"28","key":"10.1016\/j.critrevonc.2025.105059_bib46","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Octreotide LAR for tumour growth control in metastatic midgut NETs (PROMID)","volume":"27","author":"Rinke","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105059_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.21037\/tgh-24-113","article-title":"Rethinking chromogranin A: Gastrointestinal factors beyond neuroendocrine neoplasms \u2013 A narrative review","volume":"10","author":"Romano","year":"2025","journal-title":"Transl. Gastroenterol. Hepatol."},{"issue":". 7","key":"10.1016\/j.critrevonc.2025.105059_bib48","doi-asserted-by":"crossref","first-page":"S1412","DOI":"10.1016\/j.annonc.2022.08.044","article-title":"Randomized phase III SEQTOR study of everolimus followed by STZ-5FU vs the reverse sequence in advanced panNETs","volume":"33","author":"Salazar","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105059_bib49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000457954","article-title":"Bone metastases in patients with neuroendocrine neoplasm: Frequency and clinical relevance","volume":"106","author":"Scharf","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105059_bib50","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1007\/s11605-018-4011-7","article-title":"A prognostic scoring system for metastatic recurrence after curative resection of pancreatic NETs","volume":"23","author":"Sho","year":"2019","journal-title":"J. Gastrointest. Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105059_bib51","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13063-023-07834-8","article-title":"Methodology of the SORENTO trial: High-exposure octreotide depot (CAM2029) vs active control in GEP-NETs","volume":"25","author":"Singh","year":"2024","journal-title":"Trials"},{"issue":"10446","key":"10.1016\/j.critrevonc.2025.105059_bib52","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"177Lu]Lu-DOTA-TATE plus long-acting octreotide vs high-dose octreotide in newly diagnosed grade 2\u20133 GEP-NETs (NETTER-2)","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105059_bib53","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus octreotide vs high-dose octreotide in midgut NETs (NETTER-1): Final OS and long-term safety","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105059_bib54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase III trial of 177Lu-Dotatate for midgut neuroendocrine tumours","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105059_bib55","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","article-title":"Impact of liver tumour burden, alkaline phosphatase and target lesion size on outcomes with 177Lu-Dotatate: NETTER-1 analysis","volume":"47","author":"Strosberg","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105059_bib56","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of doxorubicin + fluorouracil vs streptozocin + fluorouracil or dacarbazine in advanced carcinoid tumours (E1281)","volume":"23","author":"Sun","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105059_bib57","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12902-020-0525-6","article-title":"Effect of metastatic site on survival in patients with neuroendocrine neoplasms: SEER 2010\u20132014","volume":"20","author":"Trikalinos","year":"2020","journal-title":"BMC Endocr. Disord."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105059_bib58","first-page":"8951","article-title":"Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors","volume":"15","author":"Tseng","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2025.105059_bib59","article-title":"Predictive factors for efficacy of oxaliplatin-based chemotherapy in advanced well-differentiated NETs: Cohort and meta-analysis","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105059_bib60","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/cancers14040913","article-title":"Heterogeneity of small intestinal NET metastasis: Virchow\u2019s node involvement","volume":"14","author":"Wedin","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105059_bib61","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic NETs (SANET-p): A randomized phase III trial","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105059_bib62","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic NETs (SANET-ep): A randomized phase III trial","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10022","key":"10.1016\/j.critrevonc.2025.105059_bib63","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for advanced, non-functional NETs of lung or GI tract (RADIANT-4)","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105059_bib64","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.2016.70.4072","article-title":"Octreotide + interferon vs octreotide + bevacizumab in advanced carcinoid tumours (SWOG S0518)","volume":"35","author":"Yao","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105059_bib65","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology and prognostic factors in 35,825 NET cases in the US","volume":"26","author":"Yao","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105059_bib66","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors (RADIANT-3)","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:24:47Z","timestamp":1768400687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":66,"alternative-id":["S1040842825004470"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105059","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value, clinical relevance, and methodological gaps of tumor burden in neuroendocrine tumors (NETs): A systematic review of phase III randomized trials of medical therapies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105059"}}